A sonoelectric artificial meningeal device for enhanced implantable electric field ablation of glioblastoma.

Electric field tumor therapy has emerged as a promising non-invasive treatment for glioblastoma (GBM), but its clinical efficacy is severely limited by skull-induced attenuation of electric field intensity. To overcome this limitation, we developed a multilayer thin-film sonoelectric meningeal device (MF-SMD) consisting of an electrospun PLGA artificial meningeal scaffold integrated with a microneedle-based triboelectric film. This device converts externally applied low-intensity ultrasound into intracranial electric fields, enabling transcranial, localized, and controllable electric ablation of brain tumors. Upon low-intensity ultrasound excitation, the film generates localized intracranial electric fields that disrupt tumor mitosis while preserving neuronal integrity, and significantly reduce skull-induced field attenuation. In vitro and in vivo experiments validated the antitumor efficacy of the device, achieving approximately 68% proliferation inhibition in clinical GBM cell lines and a 72% reduction in tumor burden in orthotopic mouse models. Notably, compared with conventional tumor treating fields (TTF) systems that employ extracranial electrodes, the MF-SMD maintained electric field attenuation below 20% at therapeutic frequencies. These results establish a novel therapeutic paradigm that overcomes skull-induced electric field attenuation, addressing a key challenge in transcranial brain tumor therapy.